A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)
Authors
Keywords
-
Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 29, Issue 3, Pages 151-170
Publisher
Informa UK Limited
Online
2019-03-02
DOI
10.1080/13543776.2019.1582645
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma
- (2018) Hanjie Yi et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
- (2018) Luis A. Carvajal et al. Science Translational Medicine
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Abstract 4865: BI 907828: A highly potent MDM2 inhibitor with low human dose estimation, designed for high-dose intermittent schedules in the clinic
- (2018) Joerg Rinnenthal et al. CANCER RESEARCH
- MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53
- (2018) John Hines et al. CANCER RESEARCH
- Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
- (2018) Lukasz Skalniak et al. Cancers
- MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer
- (2017) Veronica Tisato et al. Journal of Hematology & Oncology
- Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
- (2017) Ian Churcher JOURNAL OF MEDICINAL CHEMISTRY
- Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf−/−mouse model
- (2017) Emilie A. Chapeau et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma
- (2017) Viktor Arnhold et al. Oncotarget
- The Roles of MDM2 and MDMX in Cancer
- (2016) Orit Karni-Schmidt et al. Annual Review of Pathology-Mechanisms of Disease
- Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument
- (2016) Pascal Furet et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388)
- (2016) Frank Herting et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
- (2016) Joonil Jung et al. Nature Communications
- How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures
- (2015) Natalia Estrada-Ortiz et al. ChemMedChem
- Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo
- (2015) C. G. Hoffman-Luca et al. CLINICAL CANCER RESEARCH
- Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors
- (2015) Philipp Holzer et al. JOURNAL OF MEDICINAL CHEMISTRY
- A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097
- (2015) Sébastien Jeay et al. eLife
- SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression
- (2014) S. Wang et al. CANCER RESEARCH
- Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation
- (2014) Ramiro París et al. CELL CYCLE
- Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development
- (2014) Daqing Sun et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selective and Potent Morpholinone Inhibitors of the MDM2–p53 Protein–Protein Interaction
- (2014) Ana Z. Gonzalez et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design of Chemically Stable, Potent, and Efficacious MDM2 Inhibitors That Exploit the Retro-Mannich Ring-Opening-Cyclization Reaction Mechanism in Spiro-oxindoles
- (2014) Angelo Aguilar et al. JOURNAL OF MEDICINAL CHEMISTRY
- Drugging the p53 pathway: understanding the route to clinical efficacy
- (2014) Kian Hoe Khoo et al. NATURE REVIEWS DRUG DISCOVERY
- In Vitro Selection of Mutant HDM2 Resistant to Nutlin Inhibition
- (2014) Siau Jia Wei et al. PLoS One
- MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models
- (2013) C. Tovar et al. CANCER RESEARCH
- Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present)
- (2013) Krzysztof Zak et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
- (2013) Qingjie Ding et al. JOURNAL OF MEDICINAL CHEMISTRY
- Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy
- (2013) Yong S. Chang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development
- (2013) Binh Vu et al. ACS Medicinal Chemistry Letters
- Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development
- (2013) Zhuming Zhang et al. ACS Medicinal Chemistry Letters
- p53–Mdm2 inhibitors: patent review (2009 – 2010)
- (2012) Ahmed Kamal et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
- (2012) Isabelle Ray-Coquard et al. LANCET ONCOLOGY
- Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization
- (2012) B. Graves et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Structure-Based Design of Mdm2/Mdmx-p53 Inhibitors Gets Serious
- (2011) Grzegorz M. Popowicz et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- MDM-2 antagonists induce p53-dependent cell cycle arrest but not cell death in renal cancer cell lines
- (2011) Chun Chui Tsao et al. CANCER BIOLOGY & THERAPY
- Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
- (2011) M H Aziz et al. ONCOGENE
- Two-phase dynamics of p53 in the DNA damage response
- (2011) X.-P. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The p53-MDM2/MDMX axis – A chemotype perspective
- (2011) Kareem Khoury et al. MedChemComm
- Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells
- (2011) M Michaelis et al. Cell Death & Disease
- Two-Headed PROTAC: An Effective New Tool for Targeted Protein Degradation
- (2010) Kedra Cyrus et al. CHEMBIOCHEM
- Patented inhibitors of p53–Mdm2 interaction (2006 – 2008)
- (2010) Lutz Weber EXPERT OPINION ON THERAPEUTIC PATENTS
- p53 at a glance
- (2010) C. A. Brady et al. JOURNAL OF CELL SCIENCE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started